FindTrial
Sign In

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation

The Value of Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05448339
Enrollment
197
Registered
2022-07-07
Start date
2013-01-01
Completion date
2024-01-01
Last updated
2024-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Brief summary

To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. Patients are enrolled into two groups according to the downstaging therapy they undergo before transplantion.

Interventions

COMBINATION_PRODUCTPVHA or TACE

PVHA or TACE

Sponsors

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

(1) age ≥18 years; (2) exceeding UCSF criteria; (3) absence of vascular invasion, nodal involvement, or extrahepatic metastases; (4) receiving TACE treatment or LTFVD treatment for downstaging purposes.

Design outcomes

Primary

MeasureTime frameDescription
Underwent LTJanuary 2013 and December 2020Underwent LT
Successful downstagingJanuary 2013 and December 2020Successful downstaging

Secondary

MeasureTime frameDescription
AFP reduction of patientsJanuary 2013 and December 2020AFP reduction of patients
Survival time of patientsJanuary 2013 and December 2020Survival time of patients
Recurrence of patientsJanuary 2013 and December 2020Recurrence of patients

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026